



Li Jiang

■ Shanghai International College of Intellectual Property,
Tongji University, Shanghai, China ■ Current Address: 1239
Siping Road, Shanghai, P.R. China ■ Tel: +86 18658918592
■ E-mail: jelly3636@hotmail.com



Education

- 09/2009—12/2014, **Ph.D. in Law** (Bangor University, UK)
- 09/2006—07/2009, **Master of Law** (Shan Dong University, China)
- 09/2002—07/2006, **Bachelor in Biotechnology** (Beijing Science and Technology University, China)

Current Position

- 05/2019– now, **Associate Professor**, Shanghai International College of Intellectual Property, Tongji University
- 05/2015—04/2019, **Lecturer**, Kenneth Wang School of Law, Soochow University
- 05/2015—03/2019, **Researcher**, Su Zhou Intellectual Property Research Center

Research Interests

- Patent Law
- Biotechnology Law
- International Intellectual Property Law
- Medical Law

Grants

- The National Social Science Fund of China (18CFX066)
- China Postdoctoral Science Foundation (2018T110535)
- Ministry of Justice Research Foundation (17SEB3028)
- Jiangsu Philosophy and Social Science Foundation (17ZXC003)
- China Law Society Foundation (CLS(2017)Y12)
- China Postdoctoral Science Foundation (2016M590503)
- The Philosophy and Social Science Research fund of Colleges and Universities of Jiang Su Province (2016JB820023)

Publications

Book

- **Li Jiang**, *Regulating Human Embryonic Stem Cell in China- A Comparative Study on Human Embryonic Stem Cell's Patentability and Morality in US and EU*, **Springer** (2016)



Articles

- **Li Jiang**, “Commercialization of the gene-edited crop and morality: challenges from liberal patent law and strict GMO law in the EU” (2019) *New Genetic and Society* (SSCI-indexed) (forthcoming)
- **Li Jiang**, “Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent” (2018) *Science and Engineering Ethic* (SSCI-indexed) (<https://link.springer.com/article/10.1007%2Fs11948-018-0043-3>)
- **Li Jiang** and Rosemann Achim, “Human embryo gene editing in China: the uncertain legal status of the embryo” (2019) 14 *BioSocieties* 46-66. (SSCI-indexed)
- **Li Jiang**, “Centralised Intellectual Property Administrative Management Reform in China: Why it is needed and whether it works” (2018) 111 *Intellectual Property Forum* 19-24
- Achim Rosemann, Xinqing Zhang and **Li Jiang**, “Human Germ Line Gene Editing: Why Comparative, Cross-National Studies of Public Viewpoints are Important” (2017) 5 *Anthropology* 175-178.
- **Li Jiang** and Binghe Dong “Fraudsters Operate and Officialdom Turns a Blind Eye: a Proposal for Controlling Stem Cell Therapy in China” (2016) 19 *Medicine, Health Care and Philosophy* 403-410. (SSCI-indexed)
- **Li Jiang**, “Will Wild East End Scientific Feast-the First Administrative Measure on Clinical Stem Cell Research in China” (2016) 35 *Biotechnology Law Report* 27-35. (SCI-indexed)
- **Li Jiang**, “Will Diversity Regulations Disadvantage Human Embryonic Stem Cell Research: a Comparison between EU and US” (2015) 25 *DePaul Journal of Art, Technology and Intellectual Property Law* 53-90.
- **Li Jiang**, “Between Scylla and Charybdis: Patentability And Morality Related To Human Embryonic Stem Cells” (2015) 6 *American University Intellectual Property Brief* 53-97.
- **Li Jiang** and Wei Shi, “Space for Flexibility: Lessons from the European Union Harmonization Model in Human Embryonic Stem Cell Regulation” (2014) 97 *Intellectual Property Forum* 63-68.

Report

- Achim Rosemann, **Li Jiang** and Xinqing Zhang, The Regulatory and Legal Situation of Human Embryo, Gamete and Germ Line Gene Editing Research and Clinical Applications in



the People's Republic of China, Nuffield Bioethics Committee, UK, 2017.

Book Chapters

- **Li Jiang**, “The Regulation of Clinical Stem Cell in China” in Phuc Pham & Achim Rosemann (ed.), *Stem Cells in Clinical Application: Safety, Ethics and Regulation*, Springer (2017)
- **Li Jiang**, “Patentability of Human Embryo Stem Cell: A Comparative Analyse of Case WARF in United States and Europe” in H. B. Singh, A. Jha and C. Keswani (ed.), *Intellectual Property Issues in Biotechnology*, CABI (2016)

Occasions

- Reviewer, Asia Pacific Law Review
- Reviewer, Stem Cell Translational Medicine
- Reviewer, Pharmaceutical Patent Analyst